KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $5.4 million.

  • Travere Therapeutics' Other Accumulated Expenses rose 231.27% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 231.27%. This contributed to the annual value of $17.1 million for FY2024, which is 22663.74% up from last year.
  • As of Q3 2025, Travere Therapeutics' Other Accumulated Expenses stood at $5.4 million, which was up 231.27% from $14.3 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Other Accumulated Expenses peaked at $17.1 million during Q4 2024, and registered a low of $5.2 million during Q3 2024.
  • For the 5-year period, Travere Therapeutics' Other Accumulated Expenses averaged around $7.7 million, with its median value being $5.7 million (2023).
  • As far as peak fluctuations go, Travere Therapeutics' Other Accumulated Expenses crashed by 4308.87% in 2022, and later soared by 22663.74% in 2024.
  • Travere Therapeutics' Other Accumulated Expenses (Quarter) stood at $6.2 million in 2021, then fell by 7.53% to $5.7 million in 2022, then fell by 8.48% to $5.2 million in 2023, then soared by 226.64% to $17.1 million in 2024, then tumbled by 68.71% to $5.4 million in 2025.
  • Its Other Accumulated Expenses was $5.4 million in Q3 2025, compared to $14.3 million in Q2 2025 and $15.8 million in Q1 2025.